Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
Rhea-AI Summary
Anika (NASDAQ: ANIK) announced that Steve Griffin, President and CEO, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on March 2, 2026 at 11:30am CT / 12:30pm ET. Management will hold one-on-one investor meetings during the event.
The presentation will be webcast live on Anika's Events and Webcasts investor page and will be archived for 30 days. For meeting requests, contact investorrelations@anika.com.
Positive
- None.
Negative
- None.
News Market Reaction – ANIK
In the Feb 19 session, ANIK gained 1.71%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Earnings date notice | Neutral | +1.5% | Announcement of upcoming Q4 and year-end 2025 results release and call. |
| Feb 04 | Board appointment | Positive | +6.5% | Lumicell adds Anika’s Executive Chair to its board, highlighting her sector experience. |
| Jan 08 | Leadership transition | Positive | -3.0% | CEO transition to Steve Griffin with reaffirmed 2025 guidance and strategy focus. |
| Nov 05 | Q3 2025 earnings | Negative | +2.3% | Q3 revenue decline with OEM weakness despite commercial growth and cash generation. |
| Nov 05 | Clinical trial update | Negative | +2.3% | Hyalofast Phase III missed co-primary endpoints but showed post-hoc secondary benefits. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often showed divergence between headline tone and price, especially around management changes and mixed clinical/earnings updates.
Over the past several months, Anika has reported Q3 2025 results with revenue of $27.8M and a channel shift toward higher-growth commercial sales, while pursuing regulatory progress for Hyalofast despite the pivotal trial not meeting co-primary endpoints. Leadership changes were announced, elevating Steve Griffin to CEO while reaffirming fiscal 2025 guidance. Activist and institutional ownership updates appeared in regulatory filings. Today’s conference appearance fits into this backdrop of strategic repositioning, investor outreach, and ongoing clinical and commercial execution efforts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of Anika, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on Monday, March 2, 2026 at 11:30am CT / 12:30pm ET. Management will also participate in one-on-one investor meetings throughout the event.
The presentation will be webcast live on the Events and Webcasts page under the Investors section of Anika Therapeutics’ website and will be archived for 30 days following the presentation. For more information about this event or to schedule a one-on-one meeting with Anika’s senior management, please contact Anika’s Investor Relations at investorrelations@anika.com.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, ORTHOVISC, TACTOSET, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
